Preparation of potential 3-deazauridine and 6-azauridine prodrugs through an enzymatic alcoholysis

[1]  Xianfu Lin,et al.  Controllable selective synthesis of a polymerizable prodrug of cytarabine by enzymatic and chemical methods. , 2005, Bioorganic & medicinal chemistry letters.

[2]  E. Clercq,et al.  Antiviral drug discovery and development: where chemistry meets with biomedicine. , 2005, Antiviral research.

[3]  Silvio D. Rodríguez,et al.  Enzymatic alcoholysis of 3′,5′-di-O-acetyl-2′-deoxynucleosides , 2004 .

[4]  A. Iribarren,et al.  Optimisation of the lipase-catalysed preparation of a nucleoside prodrug model using an experimental design methodology , 2004 .

[5]  A. Iribarren,et al.  Regioselective preparation of 2′, 3′-di-O-acylribonucleosides carrying lipophilic acyl groups through a lipase-catalysed alcoholysis , 2002, Biotechnology Letters.

[6]  A. Iribarren,et al.  A simple and efficient enzymatic procedure for the deprotection of two base labile chlorinated purine ribosides , 2001, Biotechnology Letters.

[7]  A. Iribarren,et al.  Complete and regioselective deacetylation of peracetylated uridines using a lipase , 2000, Biotechnology Letters.

[8]  G. Wong,et al.  Pilot-Scale Lipase-Catalyzed Regioselective Acylation of Ribavirin in Anhydrous Media in the Synthesis of a Novel Prodrug Intermediate , 2003 .

[9]  Natale Scaramozzino,et al.  Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. , 2003, Antiviral research.

[10]  R. Schowen,et al.  In vitro metabolism studies of the prodrug, 2',3',5'-triacetyl-6-azauridine, utilizing an automated analytical system. , 2001, Journal of pharmaceutical and biomedical analysis.

[11]  K. Kato,et al.  Sugar-modified nucleosides in past 10 years, a review. , 2001, Current medicinal chemistry.

[12]  H. Waldmann,et al.  Enzymatic protecting group techniques. , 1994, Chemical reviews.

[13]  R. Hanson,et al.  Regioselective enzymatic aminoacylation of lobucavir to give an intermediate for lobucavir prodrug. , 2000, Bioorganic & medicinal chemistry.

[14]  V. Gotor,et al.  Biocatalytic selective modifications of conventional nucleosides, carbocyclic nucleosides, and C-nucleosides. , 2000, Chemical reviews.

[15]  E. De Clercq,et al.  Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. , 1999, Biochemical pharmacology.

[16]  E. De Clercq,et al.  Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. , 1999, Cancer research.

[17]  M. Mahmoudian,et al.  Enzymic acylation of 506U78 (2‐amino‐9‐β‐D‐arabinofuranosyl‐6‐methoxy‐9H‐purine), a powerful new anti‐leukaemic agent , 1999, Biotechnology and applied biochemistry.

[18]  H. Balfour.  Drug therapy : Antiviral drugs , 1999 .

[19]  S. Manfredini,et al.  Enzymatic Synthesis of 2′-O-acyl Prodrugs of 1-(β-D-arabinofuranosyl)-5(E)-(2-bromovinyl)uracil and of 2′-O-acyl-araU, -araC and -araA , 1998, Antiviral chemistry & chemotherapy.

[20]  P. de Miranda,et al.  Di- and triester prodrugs of the varicella-zoster antiviral agent 6-methoxypurine arabinoside. , 1992, Journal of medicinal chemistry.

[21]  A. Matsuda,et al.  A convenient method for the selective acylation of guanine nucleosides , 1986 .